Martin Bilban

Prof. Martin Bilban


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2009 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TBTilmann Bürckstümmer
Tilmann Bürckstümmer
CBChristoph Baumann
Christoph Baumann
SBStephan Blüml
Stephan Blüml
EDEvelyn Dixit
Evelyn Dixit
GDGerhard Dürnberger
Gerhard Dürnberger
GSGiulio Superti-Furga
Giulio Superti-Furga

1 June 2012 in Cell Metabolism
Verified
Journal Article
Open access
AHArvand Haschemi
Arvand Haschemi
PKPaul Kosma
Paul Kosma
LGLars Gille
Lars Gille
CECharles Evans
Charles Evans
CBCharles F. Burant
Charles F. Burant
OWOswald Wagner
Oswald Wagner
Immune cells are somewhat unique in that activation responses can alter quantitative phenotypes upwards of 100,000-fold. To date little is known about the metabolic adaptations necessary to mount such dramatic phenotypic shifts. Screening for novel regulators of macrophage activation, we found nonprotein kinases of glucose metabolism among the most enriched classes of candidate immune modulators. We find that one of these, the carbohydrate kinase-like protein CARKL, is rapidly downregulated in vitro and in vivo upon LPS stimulation in both mice and humans. Interestingly, CARKL catalyzes an orphan reaction in the pentose phosphate pathway, refocusing cellular metabolism to a high-redox state upon physiological or artificial downregulation. We find that CARKL-dependent metabolic reprogramming is required for proper M1- and M2-like macrophage polarization and uncover a rate-limiting requirement for appropriate glucose flux in macrophage polarization.

1 May 2007 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
PDF file
JSJeffrey R. Scott
Jeffrey R. Scott
BCBeek Y. Chin
Beek Y. Chin
MBMartin Bilban
Martin Bilban
LOLeo E. Otterbein
Leo E. Otterbein

15 March 2004 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
MBMartin Bilban
Martin Bilban
NGNassim Ghaffari-Tabrizi-Wizsy
Nassim Ghaffari-Tabrizi-Wizsy
EHEdith Hintermann
Edith Hintermann
SBSandra Bauer
Sandra Bauer
SMSylvia Molzer
Sylvia Molzer
Gernot DesoyeGernot Desoye
Gernot Desoye
Trophoblast invasion of the uterine extracellular matrix, a critical process of human implantation and essential for fetal development, is a striking example of controlled invasiveness. To identify molecules that regulate trophoblast invasion, mRNA signatures of trophoblast cells isolated from first trimester (high invasiveness) and term placentae (no/low invasiveness) were compared using U95A GeneChip microarrays yielding 220 invasion/migration-related genes. In this `invasion cluster', KiSS-1 and its G-protein-coupled receptor KiSS-1R were expressed at higher levels in first trimester trophoblasts than at term of gestation. Receptor and ligand mRNA and protein were localized to the trophoblast compartment. In contrast to KiSS-1, which is only expressed in the villous trophoblast, KiSS-1R was also found in the extravillous trophoblast, suggesting endocrine/paracrine activation mechanisms. The primary translation product of KiSS-1 is a 145 amino acid polypeptide (Kp-145), but shorter kisspeptins (Kp) with 10, 13, 14 or 54 amino acid residues may be produced. We identified Kp-10, a dekapeptide derived from the primary translation product, in conditioned medium of first trimester human trophoblast. Kp-10, but not other kisspeptins, increased intracellular Ca2+ levels in isolated first trimester trophoblasts. Kp-10 inhibited trophoblast migration in an explant as well as transwell assay without affecting proliferation. Suppressed motility was paralleled with suppressed gelatinolytic activity of isolated trophoblasts. These results identifed Kp-10 as a novel paracrine/endocrine regulator in fine-tuning trophoblast invasion generated by the trophoblast itself.

30 January 2007 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
BZBrian S. Zuckerbraun
Brian S. Zuckerbraun
BCBeek Yoke Chin
Beek Yoke Chin
MBMartin Bilban
Martin Bilban
Joana D'AvilaJoana D'Avila
Joana D'Avila
JRJayashree Rao
Jayashree Rao
LOLeo E. Otterbein
Leo E. Otterbein
Carbon monoxide (CO), which is produced endogenously in the breakdown of heme, has been recognized as an important physiological second messenger similar to NO. Additionally, pharmacological delivery of CO is protective in numerous models of injury, including ischemia/reperfusion, transplantation, hemorrhagic shock, and endotoxemia. However, the mechanism of action of CO is only partially elucidated focused primarily on how it modulates the cellular response to stress. The purpose of these investigations is to test the hypothesis that CO acts via inhibition of cytochrome c oxidase leading to the generation of low levels of reactive oxygen species (ROS) that in turn mediate subsequent adaptive signaling. We show here that CO increases ROS generation in RAW 264.7 cells, which is inhibited by antimycin A and is absent in respiration‐deficient p° cells. CO inhibits cytochrome c oxidase, while maintaining cellular ATP levels and increasing mitochondrial membrane potential. The addition of antioxidants or inhibition of complex III of the electron transport chain by antimycin A attenuates the inhibitory effects of CO on lipopolysaccharide (LPS)‐induced TNF‐α and blocked CO‐induced p38 MAPK phosphorylation, which we previously have shown to be important in the anti‐inflammatory effects of CO.—Zuckerbraun, B. S., Chin, B. Y., Bilban, M., de Costa d'Avila, J., Rao, J., Billiar, T. R., Otterbein, L. E. Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. FASEB J. 21, 1099–1106 (2007)

13 July 2015 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
FGFlorian Grebien
Florian Grebien
MVMasoud Vedadi
Masoud Vedadi
MGMatthäus Getlik
Matthäus Getlik
RGRoberto Giambruno
Roberto Giambruno
AGAmit Grover
Amit Grover
GSGiulio Superti-Furga
Giulio Superti-Furga
The p30 isoform of C/EBPα associated with leukemia interacts with WDR5, a component of the SET/MLL histone methyltransferase complex. A small molecule, OICR-9429, disrupted p30-WDR5 interactions, resulting in differentiation of p30-expressing leukemia cells. The CEBPA gene is mutated in 9% of patients with acute myeloid leukemia (AML). Selective expression of a short (30-kDa) CCAAT-enhancer binding protein-α (C/EBPα) translational isoform, termed p30, represents the most common type of CEBPA mutation in AML. The molecular mechanisms underlying p30-mediated transformation remain incompletely understood. We show that C/EBPα p30, but not the normal p42 isoform, preferentially interacts with Wdr5, a key component of SET/MLL (SET-domain/mixed-lineage leukemia) histone-methyltransferase complexes. Accordingly, p30-bound genomic regions were enriched for MLL-dependent H3K4me3 marks. The p30-dependent increase in self-renewal and inhibition of myeloid differentiation required Wdr5, as downregulation of the latter inhibited proliferation and restored differentiation in p30-dependent AML models. OICR-9429 is a new small-molecule antagonist of the Wdr5-MLL interaction. This compound selectively inhibited proliferation and induced differentiation in p30-expressing human AML cells. Our data reveal the mechanism of p30-dependent transformation and establish the essential p30 cofactor Wdr5 as a therapeutic target in CEBPA-mutant AML.